Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

Scientists at the <keyword id="150557" type="ORGANIZATION" weightage="20" keywordseo="University-of-Oxford">University of Oxford</keyword> have started vaccinations of a <keyword id="11578976" type="UNKNOWN" weightage="20" keywordseo="novel-hiv-vaccine">novel HIV vaccine</keyword> candidate as part of a Phase I clinical trial in the UK. The goal of the trial is to evaluate the safety, tolerability and immunogenicity of the HIVconsvX vaccine -- a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region. Thirteen healthy, HIV-negative adults, aged 18-65 and who are considered not to be at high risk of infection, will initially receive one dose of the vaccine followed by a further booster dose at four weeks. "An effective <keyword id="1180256" type="PERSON" weightage="20" keywordseo="HIV-vaccine">HIV vaccine</keyword> has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure," said lead researcher Tomas Hanke, Professor of <keyword id="11578973" type="UNKNOWN" weightage="20" keywordseo="vaccine-immunology">Vaccine Immunology</keyword> at the Jenner Institute at <keyword id="46985" type="COMPANY" weightage="20" keywordseo="Oxford">Oxford</keyword>, in a statement. While most HIV vaccine candidates work by inducing antibodies generated by B-cells, HIVconsvX induces the immune system's potent, pathogen obliterating T cells, targeting them to highly conserved and therefore vulnerable regions of HIV -- an "Achilles heel" common to most HIV variants. "Achieving protection against HIV is extremely challenging and it is important that we harness the protective potential of both the antibody and T cell arms of the immune system," said <keyword id="11578975" type="UNKNOWN" weightage="20" keywordseo="paola-cicconi">Paola Cicconi</keyword>, Senior Clinical Research Fellow at the Jenner Institute. At present, prevention of HIV largely focuses on behavioural and biomedical interventions such as voluntary medical male circumcision, condom use, and anti-retroviral drugs used prior to exposure. The researchers aim to report results of the trial by April 2022. Similar trials are also planned in Europe, Africa and the US. SEE ALSO- <a href="https://www.businessinsider.in/business/startups/news/payments-firm-pine-labs-raises-600-million-as-it-plans-to-go-public-by-2022/articleshow/84162996.cms" data-type="tilCustomLink">Payments firm Pine Labs raises $600 million as it plans to go public by 2022</a> <a href="https://www.businessinsider.in/personal-finance/news/what-happens-if-you-forget-to-claim-your-fixed-deposit-proceeds-after-maturity-explained/articleshow/84161710.cms" data-type="tilCustomLink">What happens if you forget to claim your fixed deposit proceeds after maturity? Explained</a>

In what could be a big breakthrough in medical science, researchers at the University of Oxford start phase-1 trial of a novel HIV vaccine

You Searched For "paola cicconi" and got 1 results

In what could be a big breakthrough in medical science, researchers at the University of Oxford start phase-1 trial of a novel HIV vaccine

IANS

Popular Keywords

Buying Guides